Reckoning With the Rare Disease Landscape. A 16 Country Policy Landscape Assessment across the Life Course.

No
The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.

Produced by the Global Coalition on Aging and the Global Rare Disease Policy Network, this report examines rare disease policy across 16 countries, focusing on diagnostics and screening, treatment access and reimbursement, and national policy and governance. It draws on literature review, policy analysis and stakeholder interviews.

The assessment identifies diagnostic delays, workforce shortages, fragmented care and uneven access to therapies. It considers how longer survival and population ageing affect care needs, while acknowledging limitations in cross-country comparability and evidence on rare diseases in older populations.

The report discusses the European Rare Diseases Research Alliance (ERDERA) within European research collaboration and the country profiles for France and Spain. It also references the International Rare Diseases Research Consortium (IRDiRC) in its policy timeline and discussion of international research participation. Daria Julkowska and Holm Graessner are among the acknowledged stakeholder interview contributors.

The report was developed in partnership by the two issuing organisations, with development costs funded by Biogen. Acknowledged interview contributors participated on an unpaid basis.

Year of publication

2026

Source

Global Coalition on Aging (GCOA) and Global Rare Disease Policy Network (GRDPN).

Author

You might also be interested in

The European Blueprint sets out how Europe can build on initiatives such as ERDERA to turn existing expertise into a more coordinated future for rare diseases.
November 2 @ 1:00 pm - 2:00 pm
ERDERA Ethics & Regulatory Webinar Series
Responsible data management can help accelerate research and improve collaboration in rare diseases.
New international guidance supports decentralised clinical trials, pragmatic designs and the use of real-world data.